Vaccines: market revenue in Latin America 2016-2028

The revenue of the vaccines segment of the pharmaceuticals market in Latin America was forecast to continuously increase between 2024 and 2028 by in total 0.2 billion U.S. dollars (+6.6 percent). According to this forecast, in 2028, the indicator will have increased for the third consecutive year to 3.2 billion U.S. dollars.

Revenue of the vaccines market in Latin America from 2016 to 2028 (in billion U.S. dollars)

Characteristic	Revenue in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

Citation formats